Table 1 Patients’ main characteristics
Patient | Age | Stadiation at diagnosis | PCI | Histological type | Grade | Treatment | NACT | Number of cycles | Clinical response | Time from NACT to HIPEC (days) | Previous chemotherapies | Number of cycles |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 65 | IV | 5 | Mucinous | 3 | Upfront | CBDCA+PTX | 6 | >50% | 40 | No | |
2 | 69 | IV | 0 | Serous | 2 | Upfront | CBDCA+PTX | 6 | 1 | 60 | No | |
3 | 72 | IIIc | 4 | Serous | 3 | Upfront | CBDCA+PTX | 4 | >50% | 36 | No | |
4 | 42 | IIIc | 2 | Serous | 3 | Upfront | CBDCA+PTX | 4 | >50% | 28 | No | |
5 | 59 | IIIc | 7 | Undifferentiated | 3 | Upfront | CBDCA+PTX | 3 | >50% | 30 | No | |
6 | 64 | IIIc | 3 | Undifferentiated | 3 | Upfront | CBDCA+PTX | 6 | >50% | 48 | No | |
7 | 64 | IIIc | 3 | Serous | 3 | Upfront | CBDCA+PTX | 4 | 1 | 34 | No | |
8 | 52 | IV | 4 | Serous | 3 | Relapse | No | CBDCA+PTX | 6 | |||
9 | 51 | IIIc | 4 | Endometrioid | 3 | Relapse | No | CBDCA+PTX | 5 | |||
10 | 45 | IIIc | 4 | Serous | 3 | Relapse | No | CBDCA+PTX; caelyx+yondelis | 6+10 | |||
11 | 48 | IIIc | 4 | Serous | 3 | Relapse | No | CBDCA+PTX | 6 | |||
12 | 63 | IIIc | 5 | Serous | 3 | Upfront | CBDCA+PTX | 3 | 1 | 40 | ||
13 | 51 | IIIc | 4 | Serous | 3 | Upfront | CBDCA+PTX | 3 | 1 | 36 |
